Alnylam Pharmaceuticals
ALNY
#555
Rank
ยฃ31.96 B
Marketcap
ยฃ241.05
Share price
-3.01%
Change (1 day)
18.24%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): ยฃ1.33

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is ยฃ1.36. In 2023 the company made an earnings per share (EPS) of -ยฃ2.67 an increase over its 2022 EPS that were of -ยฃ7.02.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)ยฃ1.33
2023-ยฃ2.67-62%
2022-ยฃ7.0229.03%
2021-ยฃ5.44-3.36%
2020-ยฃ5.63-8.48%
2019-ยฃ6.157.67%
2018-ยฃ5.7239.74%
2017-ยฃ4.0912.94%
2016-ยฃ3.6238.84%
2015-ยฃ2.61-32.88%
2014-ยฃ3.89259.44%
2013-ยฃ1.08-31.25%
2012-ยฃ1.57

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
ยฃ5.44 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ1.56 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
ยฃ32.60 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-ยฃ2.07-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-ยฃ0.55-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-ยฃ0.18-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ0.94-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
ยฃ0.26-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA